Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Nevro's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVRO has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NVRO exceeded the US Medical Equipment industry which returned 10.7% over the past year.
Return vs Market: NVRO exceeded the US Market which returned 10.2% over the past year.
Price Volatility Vs. Market
How volatile is Nevro's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StNevro (NYSE:NVRO) Has Debt But No Earnings; Should You Worry?
1 month ago | Simply Wall StIs Nevro Corp. (NYSE:NVRO) Trading At A 28% Discount?
2 months ago | Simply Wall StThe Nevro (NYSE:NVRO) Share Price Is Up 221% And Shareholders Are Boasting About It
Is Nevro undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NVRO ($139) is trading below our estimate of fair value ($280.85)
Significantly Below Fair Value: NVRO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NVRO is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: NVRO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NVRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NVRO is overvalued based on its PB Ratio (20.3x) compared to the US Medical Equipment industry average (3.9x).
How is Nevro forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVRO's revenue (11% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: NVRO's revenue (11% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NVRO is forecast to be unprofitable in 3 years.
How has Nevro performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVRO is currently unprofitable.
Growing Profit Margin: NVRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVRO is unprofitable, and losses have increased over the past 5 years at a rate of -14.5% per year.
Accelerating Growth: Unable to compare NVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVRO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.4%).
Return on Equity
High ROE: NVRO has a negative Return on Equity (-47.92%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Nevro's financial position?
Financial Position Analysis
Short Term Liabilities: NVRO's short term assets ($422.1M) exceed its short term liabilities ($70.6M).
Long Term Liabilities: NVRO's short term assets ($422.1M) exceed its long term liabilities ($182.7M).
Debt to Equity History and Analysis
Debt Level: NVRO's debt to equity ratio (72.5%) is considered high.
Reducing Debt: NVRO's debt to equity ratio has increased from 11.3% to 72.5% over the past 5 years.
Inventory Level: NVRO has a high level of physical assets or inventory.
Debt Coverage by Assets: NVRO's debt is covered by short term assets (assets are 2.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NVRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Nevro's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate NVRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NVRO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
D. Grossman (59yo)
Mr. D. Keith Grossman serves as a President, Chief Executive Officer and Director at Nevro Corp. since March 19, 2019 and as its Chairman of the Board since May 20, 2019. He is a Director of Alcon, Inc. He ...
|Chief Financial Officer||9.8yrs||US$693.26k||0.12% $5.1m|
|Vice President of Operations||3.9yrs||US$1.16m||0.023% $1.0m|
|General Counsel||2.2yrs||US$1.87m||0.021% $926.3k|
|Chairman of the Board||0.9yrs||no data||0.052% $2.2m|
|Vice President of Investor Relations||1.1yrs||no data||no data|
|Vice President of Marketing||3.8yrs||no data||no data|
|Vice President of Global Sales||1yrs||no data||no data|
|Chief Human Resources Officer||0.7yrs||no data||no data|
|Chief Medical Officer||5.8yrs||no data||no data|
|Chief Commercial Officer||0.7yrs||no data||no data|
Experienced Management: NVRO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Chairman of the Board||0.9yrs||no data||0.052% $2.2m|
|Independent Director||4.9yrs||US$337.94k||0.025% $1.1m|
|Independent Director||7.3yrs||US$341.94k||0.11% $4.8m|
|Independent Director||5.4yrs||US$354.94k||0.015% $626.5k|
|Independent Director||0.9yrs||no data||0.028% $1.2m|
|Independent Director||8.1yrs||US$360.19k||0.10% $4.4m|
|Lead Director||0.8yrs||US$379.94k||1.68% $72.3m|
|Independent Director||0.9yrs||no data||0.0075% $323.6k|
|Director||0.2yrs||no data||no data|
Experienced Board: NVRO's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.
Nevro Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Nevro Corp.
- Ticker: NVRO
- Exchange: NYSE
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$4.315b
- Shares outstanding: 31.82m
- Website: https://www.nevro.com
Number of Employees
- Nevro Corp.
- 1800 Bridge Parkway
- Redwood City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVRO||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Nov 2014|
|1N7||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 2014|
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 02:23|
|End of Day Share Price||2020/02/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.